BackgroundCheck.run
Search For

Simon F Semus, 6499 SE Mizner Blvd UNIT 825, Boca Raton, FL 33432

Simon Semus Phones & Addresses

Boca Raton, FL   

Malvern, PA   

2151 Ferncroft Ln, Chester Springs, PA 19425    610-4582027    610-4583426   

1275 Bridle Estates Dr, Morrisville, PA 19067    215-5793022    215-5794451   

Yardley, PA   

1530 Neshaminy Valley Dr, Bensalem, PA 19020   

Midlothian, VA   

Chester, PA   

Collegeville, PA   

Social networks

Simon F Semus
Simon F Semus

Linkedin

Work

Company: Glaxosmithkline Nov 2012 Position: Manager

Education

Degree: Doctor of Philosophy (PhD) School / High School: University of Nottingham 1982 to 1985 Specialities: Pharmaceutical Sciences

Industries

Pharmaceuticals

Mentions for Simon F Semus

Career records & work history

License Records

Simon F Semus

Address:
Morrisville, PA 19067
Licenses:
License #: RS293980 - Expired
Category: Real Estate Commission
Type: Real Estate Salesperson-Standard

Simon Frank Semus

Address:
Chester Springs, PA 19425
Licenses:
License #: RP450619 - Active
Category: Pharmacy
Type: Pharmacist

Simon Frank Semus

Address:
Chester Springs, PA 19425
Licenses:
License #: PI115151 - Expired
Category: Pharmacy
Type: Pharmacy Intern

Simon Semus resumes & CV records

Resumes

Simon Semus Photo 9

Manager At Glaxosmithkline

Position:
Manager at GlaxoSmithKline
Location:
Greater Philadelphia Area
Industry:
Pharmaceuticals
Work:
GlaxoSmithKline since Nov 2012
Manager
GlaxoSmithKline Nov 2001 - Nov 2012
Investigator
Genetics Institute / Wyeth 1998 - 2001
Principle Research Scientist
Astra 1993 - 1998
Senior Scientist
Education:
University of Nottingham 1982 - 1985
Doctor of Philosophy (PhD), Pharmaceutical Sciences
University of Portsmouth 1978 - 1981
Bachelor of Science (BSc), Pharmacy

Publications & IP owners

Us Patents

Compounds

US Patent:
6369224, Apr 9, 2002
Filed:
Jun 16, 2000
Appl. No.:
09/594703
Inventors:
Eifion Phillips - Rochester NY
Robert Mack - Rochester NY
John Macor - Flemington NJ
Simon Semus - Bensalem PA
Assignee:
Astra Zeneca AB
International Classification:
C07F 502
US Classification:
544 69, 540541, 544229, 546 13
Abstract:
A compound of formula wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H or F ; A is N or C(R ); G is N or C(R ); D is N or C(R ); with the proviso that no more than one of A, G, and D is nitrogen, but at least one of Y, A, G, and D is nitrogen or NO; R is hydrogen or C to C alkyl; R , R , and R are independently hydrogen, halogen, C -C alkyl, C -C alkenyl, C -C alkynyl, aryl, heteroaryl, OH, OC -C alkyl, CO R , âCN, âNO , âNR R , âCF , âOSO CF or R and R , or R and R , respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substituents: independently hydrogen, halogen, C -C alkyl, C -C alkenyl, C -C alkynyl, aryl, heteroaryl, OH, OC -C alkyl, CO R , âCN, âNO , âNR R , âCF , âOSO CF ; R and R are independently hydrogen, C -C alkyl, C(O)R , C(O)NHR , C(O)OR , SO R or may together be (CH ) Q(CH ) where Q is O, S, NR , or a bond; j is 2 to 7, k is 0 to 2; R , R , R , R , and R are independently C -C alkyl, aryl, or heteroaryl, or an enantiomer thereof, and the pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

Spiroazo Bicyclic Heterocyclic

US Patent:
6703502, Mar 9, 2004
Filed:
Mar 8, 2002
Appl. No.:
10/093939
Inventors:
Eifion Phillips - Rochester NY
Robert Mack - Rochester NY
John Macor - Flemington NJ
Simon Semus - Bensalem PA
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
C07D49122
US Classification:
544 70, 544230, 546 14, 546 18, 540543
Abstract:
A compound of formula wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H or F ; A is N or C(R ); G is N or C(R ); D is N or C(R ); with the proviso that no more than one of A, G, and D is nitrogen, but at least one of Y, A, G, and D is nitrogen or NO; R is hydrogen or C to C alkyl; R , R , and R are independently hydrogen, halogen, C , C alkyl, C , C alkenyl, C alkynyl, aryl, heteroaryl, OH, OC , C alkyl, CO R , âCN, âNO , âNR R , âCF , âOSO CF or R and R , or R and R , respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substituents: independently hydrogen, halogen, C -C alkyl, C -C alkenyl, C -C alkynyl, aryl, heteroaryl, OH, OC -C alkyl, CO R , âCN, âNO , âNR R , âCF , âOSO CF ; R and R are independently hydrogen, C -C alkyl, C(O)R , C(O)NHR , C(O)OR , SO R or may together be (CH ) Q(CH ) where Q is O, S, NR , or a bond; j is 2 to 7, k is 0 to 2; R , R , R , R , and R are independently C -C alkyl, aryl, or heteroaryl, or an enantiomer thereof, and the pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

Spiroazabicyclic Heterocyclic Compounds

US Patent:
6706878, Mar 16, 2004
Filed:
Mar 24, 2003
Appl. No.:
10/396215
Inventors:
Eifion Phillips - West Henrietta NY
Robert Mack - Rochester NY
John Macor - Flemington NJ
Simon Semus - Bensalem PA
Assignee:
Astrazeneca AB - Sodertalje
International Classification:
C07D49921
US Classification:
544 70, 544230, 546 14, 546 18, 540543
Abstract:
A compound of formula wherein n, m, p, X, Y, W, A, G and D are as defined in the specification, enantiomers thereof, pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

Spiroazabicyclic Heterocyclic Compounds

US Patent:
7507744, Mar 24, 2009
Filed:
Mar 15, 2004
Appl. No.:
10/801085
Inventors:
Eifion Phillips - West Henrietta NY, US
Robert Mack - Rochester NY, US
John Macor - Flemington NJ, US
Simon Semus - Bensalem PA, US
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
A61K 31/4747
C07D 221/20
US Classification:
514278, 546 16
Abstract:
A pharmaceutical composition comprising a compound of formula.

Spiroazabicyclic Heterocyclic Compounds

US Patent:
2008015, Jun 26, 2008
Filed:
Mar 13, 2008
Appl. No.:
12/047425
Inventors:
Eifion Phillips - Rochester NY, US
Robert Mack - Rochester NY, US
John Macor - Flemington NJ, US
Simon Semus - Bensalem PA, US
International Classification:
A61K 31/439
C07D 487/22
A61P 25/28
A61P 25/00
A61P 25/16
A61P 25/18
US Classification:
514278, 540466
Abstract:
A compound of formulawherein n, m, p, X, Y, W, A, G and D are as defined in the specification, enantiomers thereof, pharmaceutical compositions containing said compound, pharmaceutically acceptable salts thereof, its use in therapy, especially in the treatment of psychotic disorders and intellectual impairment disorders.

Renin Inhibitors

US Patent:
2009027, Nov 5, 2009
Filed:
Apr 5, 2007
Appl. No.:
12/225987
Inventors:
John J. Baldwin - Gwynedd Valley PA, US
David A. Claremon - Maple Glen PA, US
Colin M. Tice - Amber PA, US
Salvacion Cacatian - Blue Bell PA, US
Lawrence W. Dillard - Yardley PA, US
Alexey V. Ishchenko - Somerville MA, US
Jing Yuan - Landsdale PA, US
Zhenrong Xu - Horsham PA, US
Gerard McGeehan - Garnet Valley PA, US
Wei Zhao - Eagleville PA, US
Robert D. Simpson - Wilmington DE, US
Suresh B. Singh - Kendall park NJ, US
Patrick T. Flaherty - Pittsburgh PA, US
Lara S. Kallander - King of Prussia PA, US
Colin A. Leach - King of Prussia PA, US
Brian Lawhorn - King of Prussia PA, US
Qing Lu - King of Prussia PA, US
Lamont R. Terrell - King of Prussia PA, US
Jing Zhang - King of Prussia PA, US
Damiano Ghirlanda - King of Prussia PA, US
Xiaoping Hou - King of Prussia PA, US
Simon Semus - King of Prussia PA, US
International Classification:
A61K 31/5377
C07D 207/14
A61K 31/40
C07D 211/32
A61K 31/445
A61K 31/4545
C07D 401/10
C07D 413/06
A61P 9/12
US Classification:
5142355, 548539, 514423, 546226, 514330, 514316, 546191, 544141
Abstract:
Disclosed are compounds according to Formula I:wherein the variables are defined herein. Such compounds are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity.Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to Formula I.

Renin Inhibitors

US Patent:
2010013, May 27, 2010
Filed:
Apr 4, 2008
Appl. No.:
12/450619
Inventors:
John J. Baldwin - Gwynedd Valley PA, US
Salvacion Cacatian - Blue Bell PA, US
David Claremon - Maple Glen PA, US
Lawrence W. Dillard - Yardley PA, US
Patrick T. Flaherty - Pittsburgh PA, US
Damiamo Ghirlanda - Legnago, IT
Xiaoping Hou - Pennington NJ, US
Lara S. Kallander - King of Prussia PA, US
Beth A. Knapp-Reed - King of Prussia PA, US
Brian Lawhorn - King of Prussia PA, US
Qing Lu - King of Prussia PA, US
Gerard McGeehan - Garnet Valley PA, US
Simon Semus - Collegeville PA, US
Robert D. Simpson - Wilmington DE, US
Suresh B. Singh - Kendall Park NJ, US
Lamont R. Terrell - King of Prussia PA, US
Colin Tice - Ambler PA, US
Tritin Tran - King of Prussia PA, US
Zhenrong Xu - Horsham PA, US
Jing Yuan - Lansdale PA, US
Jing Zhang - Waltham MA, US
Wei Zhao - Eagleville PA, US
International Classification:
A61K 31/445
A61K 31/554
A61K 31/55
A61K 31/551
A61K 31/549
A61K 31/5377
A61K 31/5375
A61K 31/4545
C07D 417/12
C07D 265/30
C07D 401/06
C07D 401/10
C07D 211/34
A61P 25/00
A61P 9/12
A61P 9/10
US Classification:
51421107, 51421207, 514221, 5142235, 5142355, 5142362, 5142375, 514316, 514318, 514330, 544133, 544165, 546189, 546194, 546226
Abstract:
Described are compounds which bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.

Renin Inhibitors

US Patent:
2010028, Nov 4, 2010
Filed:
Apr 4, 2008
Appl. No.:
12/450620
Inventors:
Jonh J. Baldwin - Gwyneed Valley PA, US
Salvacion Cacatian - Blue Bell PA, US
David Claremon - Maple Glen PA, US
Lawrence W. Dillard - Yardley PA, US
Patrick T. Flaherty - Pittsburgh PA, US
John Gleason - King of Prussia PA, US
Alexey V. Ishchenko - Somerville MA, US
Brian Lawhorn - King of Prussia PA, US
Gerard McGeehan - Garnet' Valley PA, US
Jaclyn R. Patterson - King of Prussia PA, US
Simon F. Semus - Collegeville PA, US
Robert D. Simpson - Wilmington DE, US
Suresh B. Singh - Kendall Park NJ, US
Colin Tice - Ambler PA, US
Tritin Tran - King of Prussia PA, US
Zhenrong Xu - Horsham PA, US
Jing Yuan - Lansdale PA, US
Wei Zhao - Eagleville PA, US
International Classification:
A61K 31/445
C07D 211/60
C07D 401/02
C07D 413/02
A61K 31/454
A61K 31/4545
A61K 31/4709
A61K 31/496
A61K 31/5377
A61K 31/5415
A61K 31/55
A61K 31/58
A61P 9/12
US Classification:
51421207, 546245, 546208, 546189, 546146, 544365, 544130, 514330, 514326, 514316, 514307, 51425313, 5142355, 5142235, 514171
Abstract:
Disclosed are compounds of Formula I, wherein the R, R, RR, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.